β-Blockers in COPD: A Cohort Study From the TONADO Research Program.

Abstract

BACKGROUND:

Cardiovascular disease is a frequent comorbidity in patients with COPD. Many physicians, particularly pulmonologists, are reluctant to use β-adrenoceptor blocking agents (β-blockers) in patients with COPD, despite their proven effectiveness in preventing cardiovascular events.

METHODS:

The large (5,162 patients) phase III TONADO 1 and 2 studies assessed lung function and patient-reported outcomes in patients with moderate to very severe COPD receiving long-acting bronchodilator treatment across 1 year. This post hoc analysis characterized lung-function changes, patient-reported outcomes, and safety in the subgroup of patients receiving β-blockers in the studies.

RESULTS:

In total, 557 of 5,162 patients (11%) received β-blockers at baseline. Postbronchodilator FEV1 at baseline was higher in the β-blocker group (1.470 L) compared with that in the no β-blocker group (1.362 L). As expected, patients receiving β-blockers had a more frequent history of cardiovascular comorbidities and medications. Lung function improved from baseline in patients with or those without β-blocker treatment, and no relevant between-group differences were observed in trough FEV1 or trough FVC at 24 or 52 weeks. No relevant differences were observed for St. George's Respiratory Questionnaire results and Transition Dyspnea Index in patients with β-blockers compared with those in patients without. Safety findings were comparable between groups.

CONCLUSIONS:

Lung function, overall respiratory status, and safety of tiotropium/olodaterol were not influenced by baseline β-blocker treatment in patients with moderate to very severe COPD. Results from this large patient cohort support the cautious and appropriate use of β-blockers in patients with COPD and cardiovascular comorbidity.

TRIAL REGISTRY:

ClinicalTrials.gov; No.: NCT01431274 and No. NCT01431287; URL: www.clinicaltrials.gov.

• Authors: François Maltais, Roland Buhl, Andrea Koch, Valeria C Amatto, Jim Reid, Lars Grönke, Ulrich Bothner, Florian Voß, Lorcan McGarvey, Gary T Ferguson
• Journal: Chest (Chest) Vol. 153 Issue 6 Pg. 1315-1325 (06 2018) ISSN: 1931-3543 [Electronic] United States
• PMID: 29355547 (Publication Type: Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

Chemical References

• Adrenergic beta-Antagonists
• Benzoxazines
• Bronchodilator Agents
• olodaterol
• Tiotropium Bromide

Topics

• Adrenergic beta-Antagonists (administration & dosage)
• Aged
• Benzoxazines (administration & dosage)
• Bronchodilator Agents (administration & dosage)
• Double-Blind Method
• Drug Therapy, Combination
• Female
• Follow-Up Studies
• Forced Expiratory Volume
• Humans
• Male
• Middle Aged
• Pulmonary Disease, Chronic Obstructive (drug therapy)
• Tiotropium Bromide (administration & dosage)
• Treatment Outcome